Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierInstitut de Mécanique et d'Ingénierie [I2M]
dc.contributor.authorHSEIN, Hassana
hal.structure.identifierInstitut de Mécanique et d'Ingénierie [I2M]
dc.contributor.authorAUFFRAY, Julie
IDREF: 256072906
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorNOEL, Thierry
hal.structure.identifierInstitut de Mécanique et d'Ingénierie [I2M]
dc.contributor.authorTCHORELOFF, Pierre
dc.date.accessioned2023-03-16T13:14:45Z
dc.date.available2023-03-16T13:14:45Z
dc.date.issued2022-10-19
dc.identifier.issn1083-7450en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172332
dc.description.abstractEnMonoclonal antibodies constitute nowadays an important therapeutic class and the number of approved molecules for clinical uses continues to increase, achieving considerable part of the therapeutic market. Yet, the stability in solution of these biopharmaceuticals is often low. That is why freeze-drying has been and remains the method of choice to obtain monoclonal antibodies in the solid state and to improve their stability. The design of freeze-drying process and its optimization are still topical subjects of interest and the pharmaceutical industry is regularly challenged by the requirements of quality, safety and efficiency set by the regulatory authorities. These requirements imply a deep understanding of each step of the freeze-drying process, developing techniques to control the critical parameters and to monitor the quality of the intermediate and the final product. In addition to quality issues, the optimization of the freeze-drying process in order to reduce the cycle length is of great interest since freeze-drying is known to be an energy-expensive and time-consuming process. In this review, we will present the recent literature dealing with the freeze-drying of monoclonal antibodies and focus on the process parameters and strategies used to improve the stability of these molecules and to optimize the FD process.
dc.language.isoENen_US
dc.subject.enFreeze-drying
dc.subject.enMonoclonal antibodies
dc.subject.enOptimization
dc.subject.enProcess parameters
dc.subject.enProduct quality attributes
dc.subject.enStability
dc.title.enRecent advances and persistent challenges in the design of freeze-drying process for monoclonal antibodies
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/10837450.2022.2131818en_US
dc.subject.halSciences de l'ingénieur [physics]/Matériauxen_US
bordeaux.journalPharmaceutical Development and Technologyen_US
bordeaux.page942-955en_US
bordeaux.volume27en_US
bordeaux.hal.laboratoriesInstitut de Mécanique et d’Ingénierie de Bordeaux (I2M) - UMR 5295en_US
bordeaux.issue9en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionINRAEen_US
bordeaux.institutionArts et Métiersen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04032313
hal.version1
hal.date.transferred2023-03-16T13:14:47Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutical%20Development%20and%20Technology&rft.date=2022-10-19&rft.volume=27&rft.issue=9&rft.spage=942-955&rft.epage=942-955&rft.eissn=1083-7450&rft.issn=1083-7450&rft.au=HSEIN,%20Hassana&AUFFRAY,%20Julie&NOEL,%20Thierry&TCHORELOFF,%20Pierre&rft.genre=article


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record